Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - NSCLC, metastatic

LBA58 - ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial

Date

18 Sep 2020

Session

Mini Oral - NSCLC, metastatic

Presenters

Farastuk Bozorgmehr

Citation

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325

Authors

F. Bozorgmehr1, J.R. Fischer2, M. Bischof3, A. Atmaca4, S. Wetzel5, M. Faehling6, D. Bottke7, M. Wermke8, E.G..C. Troost9, G. Schmidtke-Schrezenmeier10, T. Wiegel11, V. van Laak12, A. Stupavsky13, W. Engel-Riedel14, E. Ingenhoff15, N. Reinmuth16, J. Krisam17, A. Stenzinger18, M. Thomas1, S. Rieken19

Author affiliations

  • 1 Department Of Thoracic Oncology, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE
  • 2 Department Of Thoracic Oncology, Lungenklinik Löwenstein, 74245 - Löwenstein/DE
  • 3 Department Of Radiation Oncology, Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, 74078 - Heilbronn/DE
  • 4 Klinik Für Onkologie Und Hämtologie, Nordwest-Krankenhaus, 60488 - Frankfurt am Main/DE
  • 5 Department Of Radiation Oncology, Krankenhaus Nordwest, 60488 - Frankfurt/DE
  • 6 Klinik Für Kardiologie Und Pneumologie, Klinikum Esslingen, 73730 - Esslingen am Neckar/DE
  • 7 Department Of Radiation Oncology, MVZ Hospital Esslingen, 73730 - Esslingen/DE
  • 8 Nct/ucc Early Clinical Trial Unit, Universitätsklinikum Carl Gustav Carus, 01307 - Dresden/DE
  • 9 Department Of Radiotherapy And Radiation Oncology, Technische Universität Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, 01307 - Dresden/DE
  • 10 Department Of Pneumology, University Hospital Ulm, 89081 - Ulm/DE
  • 11 Department Of Radiotherapy And Radiation Oncology, University Hospital Ulm, 89081 - Ulm/DE
  • 12 Department Of Internal Medicine, Pneumology And Sleep Medicine, DRK Kliniken Berlin Mitte, 13359 - Berlin/DE
  • 13 Department Of Radiation Oncology, DRK Kliniken Berlin Westend, 14050 - Berlin/DE
  • 14 Lungenklinik, Krankenhaus Merheim, 51109 - Köln/DE
  • 15 Department Of Radiation Oncology, City of Cologne Municipal Hospitals, 51109 - Cologne/DE
  • 16 Thoracic Oncology Department, Asklepios Fachkliniken München-Gauting, 82131 - Munich-Gauting/DE
  • 17 Institute Of Medical Biometry And Informatics, University of Heidelberg, 69120 - Heidelberg/DE
  • 18 Institute Of Pathology, Heidelberg University Hospital, 69120 - Heidelberg/DE
  • 19 Department Of Radiation Oncology, Heidelberg University Hospital, 69120 - Heidelberg/DE
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA58

Background

The FORCE trial addressed the hypothesis that applying radiation together with anti-PD-1 immunotherapies may foster immune response, by combining nivolumab and radiation in non-small cell lung cancer (NSCLC) patients with clinical indication for radiotherapy.

Methods

From 02/17-12/19, 101 patients with stage IV non-squamous NSCLC in 2nd-line or 3rd-line treatment were enrolled in this multicentre, prospective, non-randomized phase II trial. 41 patients with a clinical indication for palliative radiotherapy received nivolumab 240 mg followed by 5 x 4 Gy on consecutive days to metastasis (53% bone, 18% lymph node, 29% other), initiated 72 hours after first nivolumab administration (Group A). 60 patients without an indication for radiotherapy received nivolumab only (Group B). Nivolumab was administered every two weeks in both groups and continued until progression or limiting toxicities. In both groups, biomaterials were collected systematically for exploratory hypothesis-generating analyses.

Results

Whilst some patient baseline characteristics, e.g. age, gender, smoking status and number of previous therapies were similar in both groups, preliminary analyses indicate an imbalance with a number of unfavourable characteristics being more prevalent in group A (e.g. ECOG 1, 81% vs 58%; extrathoracic metastases, 93% vs. 63%; p<0.05). Treatment related grade 3-4 adverse events occurred at similar rates in both groups (17% vs. 15%, p=0.8). The primary objective was to achieve an objective response rate (ORR) of > 19% per RECIST criteria 1.1 in group A. With an ORR of 8.3% in group A, this target was not met (p=0.991 for one-sided binomial test). ORR in group B was 23.8%. Patients with missing tumor response assessment due to tumor-related death (group A and B: 8 and 5) were considered non-responders.

Conclusions

The combination of nivolumab and palliative radiotherapy was safe and feasible; however, it did not improve ORR in the setting of this exploration. The requirement for a clinical indication for palliative radiotherapy enforced selection of patients with unfavourable properties into group A. Clinical characteristics need consideration when assessing the efficacy of immunotherapy.

Clinical trial identification

EudraCT Nr.: 2015-005741-3; NCT03044626.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien gGmbH.

Funding

Bristol Myers Squibb.

Disclosure

F. Bozorgmehr: Research grant/Funding (self): BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self): Novartis; Honoraria (self): MSD; Honoraria (self): Chugai. A. Atmaca: Advisory/Consultancy: BMS; Advisory/Consultancy: Roche; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca. M. Faehling: Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: AstraZeneca. N. Reinmuth: Honoraria (self), Advisory/Consultancy: BMS. A. Stenzinger: Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Illumina; Advisory/Consultancy, Speaker Bureau/Expert testimony: Janssen; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Advisory/Consultancy, Speaker Bureau/Expert testimony: ThermoFischer; Research grant/Funding (institution): Chugai. M. Thomas: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (self), Travel/Accommodation/Expenses: Celgene; Honoraria (self), Travel/Accommodation/Expenses: Chugai; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings